トランスフェクション試薬＆装置の世界市場予測（～2021）：方法別、用途別（生物医学、蛋白質製造）、需要先別...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 20
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 21
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH METHODOLOGY STEPS 22
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 23
2.2.1 SECONDARY RESEARCH 23
2.2.1.1 Key data from secondary sources 23
2.2.2 PRIMARY RESEARCH 25
2.2.2.1 Key data from primary sources 26
2.2.2.2 Key insights from primary sources 26
2.2.2.3 Key industry insights 27
2.3 MARKET SIZE ESTIMATION METHODOLOGY 27
2.3.1 MARKET FORECAST METHODOLOGY 29
2.4 MARKET DATA VALIDATION AND TRIANGULATION 30
2.5 ASSUMPTIONS 31

3 EXECUTIVE SUMMARY 32
3.1 INTRODUCTION 32
3.2 CONCLUSION 36

4 PREMIUM INSIGHTS 37
4.1 GLOBAL TRANSFECTION TECHNOLOGIES MARKET 37
4.2 TRANSFECTION TECHNOLOGIES MARKET, BY APPLICATION & REGION 38
4.3 GEOGRAPHIC SNAPSHOT: TRANSFECTION TECHNOLOGIES MARKET 39
4.4 TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT (2016 VS. 2021) 40
4.5 TRANSFECTION TECHNOLOGIES MARKET, BY END USER, 2016 VS. 2021 (USD MILLION) 40

5 MARKET OVERVIEW 41
5.1 INTRODUCTION 42
5.2 MARKET DYNAMICS 42
5.2.1 DRIVERS 43
5.2.1.1 Technological advancements in transfection technology 43
5.2.1.1.1 CRISPR-Cas9 43
5.2.1.1.2 CAR-T 43
5.2.1.1.3 Three Dimension (3D) transfection technology 44
5.2.1.2 Global alliances among leading research institutes to trigger drug discovery 44
5.2.1.3 Increase in R&D spending and research activities by pharmaceutical and biotech companies 45
5.2.1.4 Growing research activities in cell science 46
5.2.1.5 Increase in demand for synthetic genes 47
5.2.1.6 Rising incidence of cancer worldwide 47
5.2.2 RESTRAINTS 47
5.2.2.1 Selective effectiveness of transfection reagents 47
5.2.2.2 Home brew reagents restrict sale of commercial kits 47
5.2.2.3 High cost of transfection reagents 48
5.2.3 OPPORTUNITIES 48
5.2.3.1 Large-scale transfections 48
5.2.3.2 High-growth opportunities in asian market 48
5.2.3.2.1 India 49
5.2.3.2.2 China 49
5.2.4 CHALLENGES 50
5.2.4.1 Transfection in hard-to-transfect cells 50
5.2.4.2 Cytotoxicity in transfection – a major concern 50

6 TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT 51
6.1 INTRODUCTION 52
6.2 REAGENTS 53
6.3 EQUIPMENT 55

7 TRANSFECTION TECHNOLOGIES MARKET, BY METHOD 56
7.1 INTRODUCTION 57
7.2 BIOCHEMICAL METHODS 58
7.2.1 LIPOFECTION 60
7.2.1.1 Advantages 60
7.2.1.2 Disadvantages 60
7.2.2 CALCIUM PHOSPHATE 61
7.2.2.1 Advantages 61
7.2.2.2 Disadvantages 62
7.2.3 DEAE-DEXTRAN 62
7.2.3.1 Advantages 62
7.2.3.2 Disadvantages 63
7.2.4 DENDRIMERS 63
7.2.4.1 Advantages 63
7.2.4.2 Disadvantages 64
7.3 PHYSICAL 64
7.3.1 ELECTROPORATION 66
7.3.1.1 Advantages 66
7.3.1.2 Disadvantages 66
7.3.2 NUCLEOFECTION 67
7.3.2.1 Advantages 67
7.3.2.2 Disadvantages 67
7.3.3 OTHER METHODS 68
7.3.3.1 Sonoporation 68
7.3.3.2 Genegun 68
7.3.3.2.1 Advantages 68
7.3.3.2.2 Disadvantages 68
7.3.3.3 Magnetofection 69
7.3.3.3.1 Advantages 69
7.3.3.3.2 Disadvantages 69
7.3.3.4 Optoinjection 69
7.3.3.4.1 Advantages 69
7.3.3.4.2 Disadvantages 69
7.4 VIRAL METHODS 70
7.4.1 ADENOVIRUSES 71
7.4.2 RETROVIRUSES 71
7.4.3 ADENOASSOCIATED VIRUSES (AAV) 71

8 TRANSFECTION TECHNOLOGIES MARKET, BY APPLICATION 73
8.1 INTRODUCTION 74
8.2 BIOMEDICAL RESEARCH 75
8.2.1 GENE EXPRESSION STUDIES 77
8.2.2 CANCER RESEARCH 78
8.2.3 TRANSGENIC MODELS 79
8.3 PROTEIN PRODUCTION 80
8.4 THERAPEUTIC DELIVERY 81

9 TRANSFECTION TECHNOLOGIES MARKET, BY END USER 83
9.1 INTRODUCTION 84
9.2 ACADEMICS & RESEARCH INSTITUTES 85
9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 86

10 TRANSFECTION TECHNOLOGIES MARKET, BY REGION 88
10.1 INTRODUCTION 89
10.2 NORTH AMERICA 90
10.2.1 U.S. 96
10.2.1.1 Increase in bio-based drug research 96
10.2.1.2 Growing demand for protein-based therapeutics triggers the growth of U.S. market 96
10.2.1.3 Increasing funding for biotechnology and for development of protein-based biologics 97
10.2.1.4 Conferences/meetings/symposiums/workshops 97
10.2.2 CANADA 102
10.2.2.1 Government support for development of protein drugs is expected to drive the market for transfection technologies 102
10.2.2.2 Increasing investments by the canadian government on regenerative medicine to drive market growth 102
10.2.2.3 Increasing funding for genome engineering in Canada likely to boost transfection technologies market 103
10.3 EUROPE 107
10.3.1 GERMANY 113
10.3.1.1 Growing biotech industry and research funding in germany 113
10.3.1.2 Collaboration among bio-pharmaceutical and biotechnology companies for the development of new vaccines is likely to drive the market growth 113
10.3.1.3 Conferences and meetings/workshops in Germany 114
10.3.1.4 Availability of funding for life science research in Germany 114
10.3.2 U.K. 118
10.3.2.1 10,000 genome project initiative in U.K. 118
10.3.2.2 Initiative to increase R&D investments in U.K. 119
10.3.3 REST OF EUROPE 123
10.3.3.1 Growing biotechnology and pharma industry in Italy 123
10.3.3.2 Focus on research in Spain 123
10.3.3.3 Investments and funding for life sciences to drive the transfection technologies market 123
10.3.3.4 Growing research investments in Sweden & Denmark 124
10.4 ASIA-PACIFIC 129
10.4.1 JAPAN 135
10.4.1.1 Rise in biomedical research in Japan 135
10.4.2 CHINA 139
10.4.2.1 Chinese government initiatives for life sciences R&D likely to boost the market 139
10.4.2.2 Industry initiative to boost transfection technology market in China 140
10.4.3 INDIA 144
10.4.3.1 Booming pharmaceutical and biotechnology industries 144
10.4.3.2 Development of bio-clusters in India 144
10.4.4 REST OF ASIA-PACIFIC 149
10.4.4.1 Federal collaborations in Australia 149
10.4.4.2 Funding for research on proteomics and genomics in Australia 149
10.4.4.3 Rising pharmaceutical and biotechnology R&D activities in South Korea 150
10.4.4.4 Government support for strong academic and commercial R&D activities in Taiwan 150
10.4.4.5 Genome Asia 100k initative 151
10.5 REST OF THE WORD (ROW) 155
10.5.1 LATIN AMERICA 155
10.5.1.1 Increasing investment in Brazil and Mexico 155
10.5.1.2 Brazil: investment in research and innovation centers and conferences & workshops 156
10.5.2 MIDDLE EAST & AFRICA 156
10.5.2.1 Increasing focus of major pharmaceutical, biopharmaceutical, and biotechnology firms in Saudi Arabia and the United Arab Emirates (UAE) and African regions 156
10.5.2.2 Genetic testing and genomic analysis in the Middle East 157

11 COMPETITIVE LANDSCAPE 161
11.1 OVERVIEW 161
11.2 MARKET SHARE ANALYSIS 162
11.2.1 INTRODUCTION 162
11.2.2 THERMO FISHER SCIENTIFIC INC. 163
11.2.3 PROMEGA CORPORATION 164
11.2.4 F. HOFFMANN-LA ROCHE LTD 164
11.2.5 QIAGEN N.V. 164
11.3 COMPETITIVE SITUATION AND TRENDS 165
11.4 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS 166
11.5 NEW PRODUCT LAUNCHES 168
11.6 EXPANSIONS 169
11.7 ACQUISITIONS 170
11.8 OTHER STRATEGIES 171

12 COMPANY PROFILES 172
(Overview, Products and Services, Financials, Strategy & Development)*
12.1 THERMO FISHER SCIENTIFIC INC. (LIFE TECHNOLOGIES) 172
12.2 PROMEGA CORPORATION 175
12.3 QIAGEN N.V. 177
12.4 F. HOFFMANN-LA ROCHE LTD 180
12.5 BIO–RAD LABORATORIES, INC. 182
12.6 MAXCYTE, INC. 184
12.7 LONZA GROUP LTD. 186
12.8 MERCK KGAA 189
12.9 POLYPLUS-TRANSFECTION SA (SUBSIDARY OF ARCHIMED) 193
12.10 MIRUS BIO LLC. 195
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13 APPENDIX 198
13.1 DISCUSSION GUIDE 198
13.2 OTHER DEVELOPMENTS 203
13.2.1 MAXCYTE INC. 203
13.2.2 LONZA GROUP LTD. 203
13.2.3 QIAGEN N.V. 203
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 204
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 206
13.5 AVAILABLE CUSTOMIZATIONS 207
13.6 RELATED REPORTS 208
13.7 AUTHOR DETAILS 209